Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

AMGEN INC.

Filed by TODD STRATEGY GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-11-01 06:26:09 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 19, 2026
Income
$80,000.00
Expenses
Not reported
Filing UUID
2954da79-59bf-4258-8118-4fe12189c8d8
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

PBM reform.

HCR · Health Issues

Cardiovascular disease awareness and treatment. Bone disease awareness and treatment. Implementation of Inflation Reduction Act. Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA).

Literal federal measure citations: H.R.1

PHA · Pharmacy

Drug pricing and patient affordability. Issues related to 340B. Biosimilars reimbursement and regulatory standards. Issues related to Supply Chain. H.R.1672: Maintaining Investments in New Innovation (MINI) Act.

Literal federal measure citations: H.R.1672

BUD · Budget/Appropriations

Appropriations. S.2: Secure America Act (Reconciliation 2.0). H.R.8800: National Defense Authorization Act for Fiscal year 2027.

Literal federal measure citations: S.2, H.R.8800

CPT · Copyright/Patent/Trademark

H.R.3160/S.1553: Promoting and Respecting Economically Viable American Innovation (PREVAIL) Act.

Literal federal measure citations: H.R.3160, S.1553

TRD · Trade (domestic/foreign)

Issues related to tariffs.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.